Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

2.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

3.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

4.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.

Health Technol Assess. 2011 Mar;15(14):1-278. doi: 10.3310/hta15140. Review.

5.

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N.

Health Technol Assess. 2011 Feb;15(10):i-xxi, 1-329. doi: 10.3310/hta15100. Review.

6.

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.

Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T.

Scand J Rheumatol. 2007 Nov-Dec;36(6):411-7. Review.

PMID:
18092260
7.

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP.

Ann Rheum Dis. 2013 Apr;72(4):517-24. doi: 10.1136/annrheumdis-2011-201244. Epub 2012 May 5. Review.

8.

[New drugs and treatment strategies for rheumatoid arthritis].

Fantini F.

Recenti Prog Med. 2003 Sep;94(9):361-79. Review. Italian.

PMID:
12942798
9.

Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.

Cawson MR, Mitchell SA, Knight C, Wildey H, Spurden D, Bird A, Orme ME.

BMC Musculoskelet Disord. 2014 Jan 20;15:26. doi: 10.1186/1471-2474-15-26. Review.

10.

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Tobin AM, Kirby B.

BioDrugs. 2005;19(1):47-57. Review.

PMID:
15691217
11.

[The role of biological agents in the treatment of psoriatic arthritis, literature review].

Koó E, Brodszky V, Péntek M, Ujfalussy I, Nagy MB, Gulácsi L.

Orv Hetil. 2006 Oct 15;147(41):1963-70. Review. Hungarian.

PMID:
17120686
12.

TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.

Wiedmann MW, Mössner J, Baerwald C, Pierer M.

Endocr Metab Immune Disord Drug Targets. 2009 Sep;9(3):295-314. Epub 2009 Sep 1. Review.

PMID:
19594416
13.

[Effectiveness of TNF antagonists in routine clinical practice and costs].

Prokes M.

Vnitr Lek. 2009 Jan;55(1):45-53. Review. Czech.

PMID:
19227955
14.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
15.

Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.

Kavanaugh A, Tutuncu Z, Catalan-Sanchez T.

Curr Opin Rheumatol. 2006 Jul;18(4):347-53. Review.

PMID:
16763453
16.

Golimumab for the treatment of psoriatic arthritis.

Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:87-95. doi: 10.3310/hta15suppl1/10. Review.

17.

Tumour necrosis factor inhibitors.

Nash PT, Florin TH.

Med J Aust. 2005 Aug 15;183(4):205-8. Review.

PMID:
16097922
18.

Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.

Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Peserico A, Puglisi Guerra A, Vena GA.

Immunopharmacol Immunotoxicol. 2012 Aug;34(4):548-60. doi: 10.3109/08923973.2011.653646. Epub 2012 Feb 2. Review.

PMID:
22296031
19.

Differentiating the efficacy of tumor necrosis factor inhibitors.

Haraoui B.

J Rheumatol Suppl. 2005 Mar;74:3-7. Review.

PMID:
15742457
20.

Supplemental Content

Support Center